000304293 001__ 304293
000304293 005__ 20250904114814.0
000304293 0247_ $$2doi$$a10.1002/cac2.70059
000304293 0247_ $$2pmid$$apmid:40898381
000304293 0247_ $$2ISSN$$a1000-467X
000304293 0247_ $$2ISSN$$a1944-446X
000304293 0247_ $$2ISSN$$a2523-3548
000304293 037__ $$aDKFZ-2025-01829
000304293 041__ $$aEnglish
000304293 082__ $$a610
000304293 1001_ $$0P:(DE-He78)d59be7ca3c039f32929e64c64ace25d9$$aHu, Yuqing$$b0$$eFirst author$$udkfz
000304293 245__ $$aRisk of colorectal cancer by family history of both colorectal carcinomas and colorectal polyps: a nationwide cohort study.
000304293 260__ $$aHoboken, NJ$$bWiley$$c2025
000304293 3367_ $$2DRIVER$$aarticle
000304293 3367_ $$2DataCite$$aOutput Types/Journal article
000304293 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756967992_27123
000304293 3367_ $$2BibTeX$$aARTICLE
000304293 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304293 3367_ $$00$$2EndNote$$aJournal Article
000304293 500__ $$a#EA:C120#LA:C120# / epub
000304293 520__ $$aThe increased risk of colorectal cancer (CRC) associated with family history of both colorectal in situ or invasive carcinomas (Stage 0 to IV) and colorectal polyps is attributed solely to family history of CRC, resulting in an underestimation of the actual risk. We aimed to assess the association between overall and early-onset CRC (EOCRC) risk and family history of both colorectal carcinomas and polyps.We conducted a nationwide cohort study leveraging Swedish family-cancer datasets with follow-up from 1964 to 2018. Standardized incidence ratios (SIRs) were calculated to estimate the risk of CRC and EOCRC among individuals with a family history of both colorectal polyps and carcinomas.We followed up 13,432,205 individuals for up to 54 years. The risk of overall CRC was 2.2 times increased in individuals with 1 first-degree relative (FDR) with one-time polyp diagnosis and an additional FDR with carcinoma (95% CI = 2.1-2.3; EOCRC SIR = 2.9 [95% CI = 2.4-3.4]). The risk was significantly higher in individuals with 1 FDR with repeated polyp diagnoses (≥2 times) and an additional FDR with carcinoma (overall SIR = 2.9 [95% CI = 2.7-3.1]; EOCRC SIR = 5.4 [95% CI = 3.9-6.4]). A similar risk was observed in individuals with ≥2 FDRs with one-time polyp diagnosis and an additional FDR with carcinoma (overall SIR = 2.9 [95% CI = 2.4-3.4]; EOCRC SIR = 5.3 [95% CI = 3.0-8.6]). Individuals with ≥2 FDRs with repeated polyp diagnoses and an additional FDR with carcinoma had a 5.0-fold overall risk (95% CI = 4.3-5.7) and a 13.8-fold EOCRC risk (95% CI = 9.7-20.1). Younger age at polyp/carcinoma diagnoses, and more relatives with polyps and carcinomas were associated with higher CRC risk.Individuals with a family history of both colorectal polyps and carcinomas are at significantly increased risk of CRC, especially EOCRC. The risk increased with frequent polyp diagnoses, younger age at first polyp/carcinoma diagnoses, and the number of relatives with polyps/carcinomas. This study highlights the importance of considering both colorectal polyps and carcinomas in family history when assessing CRC risk. These findings could supplement current screening guidelines.
000304293 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000304293 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304293 650_7 $$2Other$$acolorectal cancer
000304293 650_7 $$2Other$$acolorectal polyp
000304293 650_7 $$2Other$$aearly‐onset colorectal cancer
000304293 650_7 $$2Other$$afamily history
000304293 7001_ $$aKharazmi, Elham$$b1
000304293 7001_ $$0P:(DE-He78)59bc83ea3f8c2a5ef6118233f87b5e68$$aLiang, Qunfeng$$b2$$udkfz
000304293 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$udkfz
000304293 7001_ $$aSundquist, Jan$$b4
000304293 7001_ $$aSundquist, Kristina$$b5
000304293 7001_ $$0P:(DE-He78)b510b884502b619724039bf33fdae68a$$aFallah, Mahdi$$b6$$eLast author$$udkfz
000304293 773__ $$0PERI:(DE-600)2922913-3$$a10.1002/cac2.70059$$gp. cac2.70059$$pnn$$tCancer communications$$vnn$$x1000-467X$$y2025
000304293 909CO $$ooai:inrepo02.dkfz.de:304293$$pVDB
000304293 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d59be7ca3c039f32929e64c64ace25d9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304293 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)59bc83ea3f8c2a5ef6118233f87b5e68$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000304293 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000304293 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b510b884502b619724039bf33fdae68a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000304293 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000304293 9141_ $$y2025
000304293 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:05:11Z
000304293 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:05:11Z
000304293 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T09:05:11Z
000304293 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-05-02T09:05:11Z
000304293 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER COMMUN : 2022$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bCANCER COMMUN : 2022$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000304293 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000304293 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x0
000304293 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x0
000304293 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x1
000304293 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x0
000304293 980__ $$ajournal
000304293 980__ $$aVDB
000304293 980__ $$aI:(DE-He78)C120-20160331
000304293 980__ $$aI:(DE-He78)C070-20160331
000304293 980__ $$aUNRESTRICTED